TRANSCRIPTIONAL ACTIVITY OF CANCER-TESTIS ANTIGENS IN PATIENTS WITH BREAST CANCER OF LUMINAL SUBTYPES A AND B
To identify new molecular markers of breast cancer and effective targets for immunotherapy, based on cancer-testicular antigens (CTA), an analysis of the association of CTA gene expression with the clinical and pathological characteristics (such as luminal subtype A / B and age of patients) of breast cancer is needed. The expression analysis of 17 genetic loci (MAGEA1, MAGEA2, MAGEA3, MAGEA4, MAGEB1, MAGEB2, GAGE1, GAGE3, GAGE4, MAGEC1, BAGE, CTAG1B, XAGE3, NY-ESO1, SSX2, SYCP1 and PRAME1) was performed by RT-qPCR in 50 samples of breast tissue. It was found that the transcriptional activity of CTA differs in different age groups of patients (up to 55 years - overexpression of MAGEA3, after 55 years - MAGEA1, MAGEB1, BAGE, CTAG1B, GAGE1 and GAGE3) and breast cancer subtypes (in luminal subtype A - overexpression of MAGEA1, MAGEA2, MAGEA4, MAGEB1, MAGEB2, GAGE3, GAGE4, MAGEC1 and PRAME1, in luminal subtype B - no one genes with increased expression). These differences should be considered when planning immunotherapy and can be used as biomarkers.